Figure 6: UVRAG^FS sensitizes CRC to DNA damage-inducing chemotherapy.

(a) Mice bearing SW480.Vec and SW480.UVRAG^FS tumours were treated with saline or 5-FU over day 1–30 when the tumour volume reached 200 mm^3. Mean relative tumour volume (n=10), is expressed compared with tumour volumes on day 1. *P<0.05; **P<0.01; ***P<0.001. (b) Relative tumour volume for individual mice treated in a at day 25. (c) Representative images of mice bearing SW480-xenografts on the day 0, 21–28 of chemotherapy (left). Western blots showed UVRAG^FS expression in representative tumours. Scale bar, 5 mm. (d) Immunohistochemical analysis of SW480-xenografts harvested from mice treated for 28 continuous days with 5-FU. Representative sections were stained (left) as indicated and staining-positive cells were quantified (right) as means±s.d. Scale bar, 10 μm. *P<0.05; **P<0.01; ***P<0.001. (e) SW480.Vector, SW480.UVRAG^WT and SW480.UVRAG^FS were treated with the indicated doses of 5-FU, Oxaliplatin and Irinotecan, followed by colony survival assay. Data are the means±s.d. (n=3). *P<0.05; **P<0.01.